In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Bio-Techne's current price exceeds all valuation models, indicating significant overvaluation risk with implied downside over 50%. Financial health reveals strong liquidity and leverage but weak profitability and growth, increasing volatility (CV 42.68%) and downside risk (100% scenarios below price). Monte Carlo median valuation at $17.87 supports valuation concerns amid high uncertainty.